Why You Might Be Interested In ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) For Its Upcoming Dividend
Why You Might Be Interested In ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) For Its Upcoming Dividend
It looks like ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) is about to go ex-dividend in the next 2 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. Therefore, if you purchase ZhuZhou QianJin PharmaceuticalLtd's shares on or after the 27th of June, you won't be eligible to receive the dividend, when it is paid on the 27th of June.
千金藥業(SHSE:600479)看來即將在未來2天內進行分紅派息。分紅派息日期是公司公佈決定哪些股東有權獲得分紅的日期前1個營業日。了解分紅派息日期很重要,因爲在公佈股東名單的日期前或當天,必須完成任何該股票的交易結算。因此,如果您在6月27日或之後購買千金藥業的股票,則無法在6月27日支付分紅時獲得分紅。
The company's next dividend payment will be CN¥0.35 per share, on the back of last year when the company paid a total of CN¥0.35 to shareholders. Looking at the last 12 months of distributions, ZhuZhou QianJin PharmaceuticalLtd has a trailing yield of approximately 3.4% on its current stock price of CN¥10.20. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.
該公司的下一筆股息支付將爲每股CN¥0.35,在上一年公司向股東支付總共CN¥0.35的基礎上。查看過去12個月的分配,千金藥業的股票當前價格爲CN¥10.20,其悠久回報率約爲3.4%。 對於長揸者而言,股息是投資回報的主要貢獻者,但前提是股息繼續支付。這就是爲什麼我們應該始終檢查分紅是否可持續,並檢查公司是否在增長。
Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Fortunately ZhuZhou QianJin PharmaceuticalLtd's payout ratio is modest, at just 46% of profit. A useful secondary check can be to evaluate whether ZhuZhou QianJin PharmaceuticalLtd generated enough free cash flow to afford its dividend. It distributed 34% of its free cash flow as dividends, a comfortable payout level for most companies.
分紅通常是由公司收入支付的,因此,如果公司支付的分紅超過它賺取的金額,其分紅通常面臨更高的風險。幸運的是,千金藥業的派息比率非常適中,僅爲利潤的46%。一個有用的輔助檢查是評估千金藥業是否產生足夠的自由現金流來支付其分紅。它將其自由現金流的34%分配爲分紅,這對大多數公司而言是適當的派息水平。
It's positive to see that ZhuZhou QianJin PharmaceuticalLtd's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
值得注意的是,千金藥業的股息被利潤和現金流覆蓋,因爲這通常是該股息可持續的標誌,較低的派息比率通常表明在分紅被削減前較大的安全保障。
Click here to see how much of its profit ZhuZhou QianJin PharmaceuticalLtd paid out over the last 12 months.
點擊此處查看千金藥業過去12個月內支付了多少利潤。
![historic-dividend](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-934d36ba029331a69a136007ff0fb8c3-0-d6f91643b6cae4f4ed4a8509907a0a0e.png/big)
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. With that in mind, we're encouraged by the steady growth at ZhuZhou QianJin PharmaceuticalLtd, with earnings per share up 4.5% on average over the last five years. Earnings per share growth in recent times has not been a standout. Yet there are several ways to grow the dividend, and one of them is simply that the company may choose to pay out more of its earnings as dividends.
一般而言, 持續增長收益每股股利的公司通常成爲最佳股息股,因爲他們通常更容易增加每股股息。如果收益下降,公司被迫削減股息,則投資者可能會看到他們投資的價值化爲烏有。考慮到這一點,我們鼓勵朱州千金藥業有限公司穩步增長,過去五年中每股收益平均增長4.5%。近段時間每股收益的增長沒有脫穎而出。但增加股息的方法有幾種,其中一種就是公司可以選擇更多地支付其收益作爲股息。
The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. In the last 10 years, ZhuZhou QianJin PharmaceuticalLtd has lifted its dividend by approximately 8.8% a year on average. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders.
大多數投資者評估一家公司的股息前景的主要方式是通過檢查其歷史股息增長率。 在過去的10年中,朱州千金藥業有限公司平均每年提高股息約8.8%。看到公司在收益增長時提高股息是令人鼓舞的,至少表明公司有意獎勵股東。
Final Takeaway
最後的結論
From a dividend perspective, should investors buy or avoid ZhuZhou QianJin PharmaceuticalLtd? Earnings per share growth has been growing somewhat, and ZhuZhou QianJin PharmaceuticalLtd is paying out less than half its earnings and cash flow as dividends. This is interesting for a few reasons, as it suggests management may be reinvesting heavily in the business, but it also provides room to increase the dividend in time. It might be nice to see earnings growing faster, but ZhuZhou QianJin PharmaceuticalLtd is being conservative with its dividend payouts and could still perform reasonably over the long run. Overall we think this is an attractive combination and worthy of further research.
從股息的角度來看,投資者應該買還是避開朱州千金藥業有限公司?每股收益增長有所增長,而朱州千金藥業有限公司支付的股息和現金流不到一半。這是有趣的,因爲它表明管理層可能在大量重新投資業務,但這也提供了逐漸提高股息的空間。看到收益增長得更快可能很好,但朱州千金藥業有限公司在其股息支付上保守,長期內仍然表現良好。總體而言,我們認爲這是一個有吸引力的組合,值得進一步研究。
So while ZhuZhou QianJin PharmaceuticalLtd looks good from a dividend perspective, it's always worthwhile being up to date with the risks involved in this stock. For example - ZhuZhou QianJin PharmaceuticalLtd has 1 warning sign we think you should be aware of.
因此,儘管千金藥業在股息方面看起來不錯,但隨時了解此股票的風險仍然值得。例如,千金藥業有1個警告標誌,我們認爲您應該知道。
If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.
如果你在尋找強勁的股息支付者,我們建議查看我們的頂級股息股票選擇。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com